Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PLT 012

Next Previous
Drug Profile

PLT 012

Alternative Names: PLT-012

Latest Information Update: 17 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pilatus Biosciences
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD36 antigen antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Liver cancer
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Immunological disorders; Liver cancer; Liver metastases; Solid tumours

Most Recent Events

  • 14 Oct 2025 Pilatus Biosciences has patent protection covering “Methods for Modulating Regulatory T Cells and Inhibiting Tumor Growth” in Europe and Australia
  • 13 Aug 2025 Pilatus Biosciences collaborates with Roche for atezolizumab
  • 13 Aug 2025 Pilatus Biosciences plans a phase I first-in-human trial for Liver cancer (Combination therapy) in USA (Parenteral), in 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top